Literature DB >> 23072969

Serum glutamate levels correlate with Gleason score and glutamate blockade decreases proliferation, migration, and invasion and induces apoptosis in prostate cancer cells.

Shahriar Koochekpour1, Sunipa Majumdar, Gissou Azabdaftari, Kristopher Attwood, Ray Scioneaux, Dhatchayini Subramani, Charles Manhardt, Giovanni D Lorusso, Stacey S Willard, Hillary Thompson, Mojgan Shourideh, Katayoon Rezaei, Oliver Sartor, James L Mohler, Robert L Vessella.   

Abstract

PURPOSE: During glutaminolysis, glutamine is catabolized to glutamate and incorporated into citric acid cycle and lipogenesis. Serum glutamate levels were measured in patients with primary prostate cancer or metastatic castrate-resistant prostate cancer (mCRPCa) to establish clinical relevance. The effect of glutamate deprivation or blockade by metabotropic glutamate receptor 1 (GRM1) antagonists was investigated on prostate cancer cells' growth, migration, and invasion to establish biologic relevance. EXPERIMENTAL
DESIGN: Serum glutamate levels were measured in normal men (n = 60) and patients with primary prostate cancer (n = 197) or mCRPCa (n = 109). GRM1 expression in prostatic tissues was examined using immunohistochemistry (IHC). Cell growth, migration, and invasion were determined using cell cytotoxicity and modified Boyden chamber assays, respectively. Apoptosis was detected using immunoblotting against cleaved caspases, PARP, and γ-H2AX.
RESULTS: Univariate and multivariate analyses showed significantly higher serum glutamate levels in Gleason score ≥ 8 than in the Gleason score ≤ 7 and in African Americans than in the Caucasian Americans. African Americans with mCRPCa had significantly higher serum glutamate levels than those with primary prostate cancer or benign prostate. However, in Caucasian Americans, serum glutamate levels were similar in normal research subjects and patients with mCRPC. IHC showed weak or no expression of GRM1 in luminal acinar epithelial cells of normal or hyperplastic glands but high expression in primary or metastatic prostate cancer tissues. Glutamate deprivation or blockade decreased prostate cancer cells' proliferation, migration, and invasion and led to apoptotic cell death.
CONCLUSIONS: Glutamate expression is mechanistically associated with and may provide a biomarker of prostate cancer aggressiveness. ©2012 AACR

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23072969      PMCID: PMC3492499          DOI: 10.1158/1078-0432.CCR-12-1308

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

1.  Akt stimulates aerobic glycolysis in cancer cells.

Authors:  Rebecca L Elstrom; Daniel E Bauer; Monica Buzzai; Robyn Karnauskas; Marian H Harris; David R Plas; Hongming Zhuang; Ryan M Cinalli; Abass Alavi; Charles M Rudin; Craig B Thompson
Journal:  Cancer Res       Date:  2004-06-01       Impact factor: 12.701

2.  Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II.

Authors:  Cyril Barinka; Markéta Rinnová; Pavel Sácha; Camilo Rojas; Pavel Majer; Barbara S Slusher; Jan Konvalinka
Journal:  J Neurochem       Date:  2002-02       Impact factor: 5.372

3.  BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity.

Authors:  F Y Carroll; A Stolle; P M Beart; A Voerste; I Brabet; F Mauler; C Joly; H Antonicek; J Bockaert; T Müller; J P Pin; L Prézeau
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

4.  Initiation of DNA fragmentation during apoptosis induces phosphorylation of H2AX histone at serine 139.

Authors:  E P Rogakou; W Nieves-Neira; C Boon; Y Pommier; W M Bonner
Journal:  J Biol Chem       Date:  2000-03-31       Impact factor: 5.157

Review 5.  Glutamate: an amino acid of particular distinction.

Authors:  V R Young; A M Ajami
Journal:  J Nutr       Date:  2000-04       Impact factor: 4.798

6.  Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia.

Authors:  Pamela M Pollock; Karine Cohen-Solal; Raman Sood; Jin Namkoong; Jeffrey J Martino; Aruna Koganti; Hua Zhu; Christiane Robbins; Izabela Makalowska; Seung-Shick Shin; Yari Marin; Kathleen G Roberts; Laura M Yudt; Amy Chen; Jun Cheng; Arturo Incao; Heather W Pinkett; Christopher L Graham; Karen Dunn; Steven M Crespo-Carbone; Kerine R Mackason; Kevin B Ryan; Daniel Sinsimer; James Goydos; Kenneth R Reuhl; Michael Eckhaus; Paul S Meltzer; William J Pavan; Jeffrey M Trent; Suzie Chen
Journal:  Nat Genet       Date:  2003-05       Impact factor: 38.330

7.  Metabotropic glutamate receptor-1: a potential therapeutic target for the treatment of breast cancer.

Authors:  Cecilia L Speyer; Jennifer S Smith; Malathi Banda; John A DeVries; Tassia Mekani; David H Gorski
Journal:  Breast Cancer Res Treat       Date:  2011-06-17       Impact factor: 4.872

8.  Glutamate release promotes growth of malignant gliomas.

Authors:  T Takano; J H Lin; G Arcuino; Q Gao; J Yang; M Nedergaard
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

9.  Racial variation in prostate cancer incidence and in hormonal system markers among male health professionals.

Authors:  E A Platz; E B Rimm; W C Willett; P W Kantoff; E Giovannucci
Journal:  J Natl Cancer Inst       Date:  2000-12-20       Impact factor: 13.506

10.  Glutamate antagonists limit tumor growth.

Authors:  W Rzeski; L Turski; C Ikonomidou
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-01       Impact factor: 11.205

View more
  57 in total

1.  Glutamate, a metabolic biomarker of aggressiveness and a potential therapeutic target for prostate cancer.

Authors:  Shahriar Koochekpour
Journal:  Asian J Androl       Date:  2013-01-14       Impact factor: 3.285

2.  A Novel [15N] Glutamine Flux using LC-MS/MS-SRM for Determination of Nucleosides and Nucleobases.

Authors:  Feng Jin; Salil Kumar Bhowmik; Vasanta Putluri; Franklin Gu; Jie Gohlke; Friedrich Carl Von Rundstedt; Subhamoy Dasgupta; Rashmi Krishnapuram; Bert W O'Malley; Arun Sreekumar; Nagireddy Putluri
Journal:  J Anal Bioanal Tech       Date:  2015-08-30

3.  Metabotropic glutamate receptor 1 disrupts mammary acinar architecture and initiates malignant transformation of mammary epithelial cells.

Authors:  Jessica L F Teh; Raj Shah; Stephanie La Cava; Sonia C Dolfi; Madhura S Mehta; Sameera Kongara; Sandy Price; Shridar Ganesan; Kenneth R Reuhl; Kim M Hirshfield; Vassiliki Karantza; Suzie Chen
Journal:  Breast Cancer Res Treat       Date:  2015-04-10       Impact factor: 4.872

4.  Small interfering RNA-mediated knockdown of fatty acid synthase attenuates the proliferation and metastasis of human gastric cancer cells via the mTOR/Gli1 signaling pathway.

Authors:  Liang Sun; Yizhou Yao; Guofeng Pan; Shenghua Zhan; Weiqiang Shi; Ting Lu; Jinfeng Yuan; Kangjun Tian; Linhua Jiang; Shiduo Song; Xinguo Zhu; Songbing He
Journal:  Oncol Lett       Date:  2018-05-07       Impact factor: 2.967

5.  18F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.

Authors:  Hakan Öztürk; Inanç Karapolat
Journal:  Oncol Lett       Date:  2015-11-10       Impact factor: 2.967

6.  Diagnosis of prostate cancer by desorption electrospray ionization mass spectrometric imaging of small metabolites and lipids.

Authors:  Shibdas Banerjee; Richard N Zare; Robert J Tibshirani; Christian A Kunder; Rosalie Nolley; Richard Fan; James D Brooks; Geoffrey A Sonn
Journal:  Proc Natl Acad Sci U S A       Date:  2017-03-14       Impact factor: 11.205

7.  Concurrent Targeting of Glutaminolysis and Metabotropic Glutamate Receptor 1 (GRM1) Reduces Glutamate Bioavailability in GRM1+ Melanoma.

Authors:  Raj Shah; Simar J Singh; Fabian V Filipp; Suzie Chen; Kevinn Eddy
Journal:  Cancer Res       Date:  2019-04-15       Impact factor: 12.701

8.  Metabolic reprogramming and validation of hyperpolarized 13C lactate as a prostate cancer biomarker using a human prostate tissue slice culture bioreactor.

Authors:  Kayvan R Keshari; Renuka Sriram; Mark Van Criekinge; David M Wilson; Zhen J Wang; Daniel B Vigneron; Donna M Peehl; John Kurhanewicz
Journal:  Prostate       Date:  2013-03-26       Impact factor: 4.104

9.  A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.

Authors:  Janice M Mehnert; Ann W Silk; J H Lee; Liesel Dudek; Byeong-Seon Jeong; Jiadong Li; Jason M Schenkel; Evita Sadimin; Michael Kane; Hongxia Lin; Weichung J Shih; Andrew Zloza; Suzie Chen; James S Goydos
Journal:  Pigment Cell Melanoma Res       Date:  2018-04-10       Impact factor: 4.693

10.  Stromal epigenetic alterations drive metabolic and neuroendocrine prostate cancer reprogramming.

Authors:  Rajeev Mishra; Subhash Haldar; Veronica Placencio; Anisha Madhav; Krizia Rohena-Rivera; Priyanka Agarwal; Frank Duong; Bryan Angara; Manisha Tripathi; Zhenqiu Liu; Roberta A Gottlieb; Shawn Wagner; Edwin M Posadas; Neil A Bhowmick
Journal:  J Clin Invest       Date:  2018-07-26       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.